phenelzine has been researched along with Refractory Depression in 2 studies
Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.
Excerpt | Relevance | Reference |
---|---|---|
" By study phase, Eight of 27 (30%) patients remitted with initial dosing of tranylcypromine up to 60 mg/d, 6/18 (33%) remitted with above PDR dosing of tranylcypromine up to 120 mg/d, and 1/6 (17%) to adding dextroamphetamine." | 2.79 | How treatable is refractory depression? ( Deliyannides, DA; McGrath, PJ; Stewart, JW, 2014) |
"Evidence supports the use of MAOIs in major depressive disorder, certain anxiety disorders and, to lesser extent, bipolar depression." | 2.53 | MAOIs - does the evidence warrant their resurrection? ( Bosanac, P; Castle, D; Menkes, D, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Stewart, JW | 1 |
Deliyannides, DA | 1 |
McGrath, PJ | 1 |
Menkes, D | 1 |
Bosanac, P | 1 |
Castle, D | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Pilot Study of Treatment for Refractory Depression With Sequential Trials of Tranylcypromine, Tranylcypromine Plus Dextroamphetamine, Tranylcypromine Plus Triiodothyronine.[NCT00296686] | Phase 4 | 31 participants (Actual) | Interventional | 2001-09-30 | Terminated (stopped due to Study is no longer funded.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for phenelzine and Refractory Depression
Article | Year |
---|---|
MAOIs - does the evidence warrant their resurrection?
Topics: Anxiety Disorders; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resi | 2016 |
1 trial available for phenelzine and Refractory Depression
Article | Year |
---|---|
How treatable is refractory depression?
Topics: Adult; Antidepressive Agents; Central Nervous System Stimulants; Depressive Disorder, Major; Depress | 2014 |